CNGB1 and Allied Disorders

Last updated: May 31, 2024
Sponsor: Columbia University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Eye Disorders/infections

Posterior Uveitis

Retinitis Pigmentosa

Treatment

No intervention, this is a natural history progression study

Clinical Study ID

NCT04639635
AAAS1160
  • All Genders

Study Summary

Mutations in the rod-expressed gene, cyclic nucleotide-gated channel beta subunit (CNGB1) and associated inborn errors in metabolism are causes of retinal disease that causes progressive loss of vision. Retinitis pigmentosa (RP) is a major cause of untreatable blindness associated with CNGB1 (CNGB1-RP). RP involves the death of photoreceptor cells that can be caused by mutations in a number of different genes. Treatment by gene therapy could prevent blindness in cases of inherited retinal dystrophies including RP. In the future RP due to mutations in CNGB1 may be treatable by gene therapy since this form of photoreceptor degeneration involves a slow loss of rod photoreceptor cells. This provides a wide window of opportunity for the identification of patients and initiation of treatment. Our efforts are directed toward developing gene therapy as a treatment. To this end, our objective is to better understand the disease process of CNGB1-RP and other allied inherited disorders so that we can develop clinical tests to measure the outcomes of treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of CNGB1-associated RP by study physician, who are trained retinal specialists in the university clinic

  • Must be able to commit to 4 follow-up study visits (3 years)

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: No intervention, this is a natural history progression study
Phase:
Study Start date:
March 14, 2019
Estimated Completion Date:
January 31, 2026

Connect with a study center

  • Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts

    Paris,
    France

    Active - Recruiting

  • Klinikum der Universität München University Eye Hospital, Ludwig-Maximilians-University (LMU) Munich

    München, Bavaria 80336
    Germany

    Active - Recruiting

  • Eberhard Karls University Tubingen

    Tuebingen,
    Germany

    Active - Recruiting

  • Moorfields Eye Hospital NHS Foundation Trust

    London,
    United Kingdom

    Site Not Available

  • Dr. Stephen H. Tsang

    New York, New York 10032
    United States

    Active - Recruiting

  • Wills Eye Hospital

    Philadelphia, Pennsylvania 19107
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.